JP2014512808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512808A5 JP2014512808A5 JP2013556905A JP2013556905A JP2014512808A5 JP 2014512808 A5 JP2014512808 A5 JP 2014512808A5 JP 2013556905 A JP2013556905 A JP 2013556905A JP 2013556905 A JP2013556905 A JP 2013556905A JP 2014512808 A5 JP2014512808 A5 JP 2014512808A5
- Authority
- JP
- Japan
- Prior art keywords
- proteins
- disease
- transcription factor
- mammal
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 102000040945 Transcription factor Human genes 0.000 claims 14
- 108091023040 Transcription factor Proteins 0.000 claims 14
- 239000003446 ligand Substances 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 102000003951 Erythropoietin Human genes 0.000 claims 9
- 108090000394 Erythropoietin Proteins 0.000 claims 9
- 229940105423 erythropoietin Drugs 0.000 claims 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 241000702421 Dependoparvovirus Species 0.000 claims 4
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 4
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 4
- 102000003996 Interferon-beta Human genes 0.000 claims 4
- 108090000467 Interferon-beta Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 4
- 229960001388 interferon-beta Drugs 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010019860 Hereditary angioedema Diseases 0.000 claims 3
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 102000011690 Adiponectin Human genes 0.000 claims 2
- 108010076365 Adiponectin Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101710085045 B2 bradykinin receptor Proteins 0.000 claims 2
- 102400000967 Bradykinin Human genes 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- 208000031964 Other metabolic disease Diseases 0.000 claims 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229940076144 interleukin-10 Drugs 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010028774 Complement C1 Proteins 0.000 claims 1
- 102100025406 Complement C1s subcomponent Human genes 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 claims 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 claims 1
- 102100023012 Kallistatin Human genes 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 1
- 206010068690 Pulmonary vein occlusion Diseases 0.000 claims 1
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000005980 lung dysfunction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449536P | 2011-03-04 | 2011-03-04 | |
| US61/449,536 | 2011-03-04 | ||
| US201161478881P | 2011-04-25 | 2011-04-25 | |
| US61/478,881 | 2011-04-25 | ||
| US201161490535P | 2011-05-26 | 2011-05-26 | |
| US61/490,535 | 2011-05-26 | ||
| US201161562342P | 2011-11-21 | 2011-11-21 | |
| US61/562,342 | 2011-11-21 | ||
| PCT/US2012/027515 WO2012122025A2 (en) | 2011-03-04 | 2012-03-02 | Vectors conditionally expressing protein |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044305A Division JP2017141245A (ja) | 2011-03-04 | 2017-03-08 | タンパク質を条件的に発現するベクター |
| JP2017125428A Division JP2017212995A (ja) | 2011-03-04 | 2017-06-27 | タンパク質を条件的に発現するベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512808A JP2014512808A (ja) | 2014-05-29 |
| JP2014512808A5 true JP2014512808A5 (enExample) | 2015-04-16 |
| JP6189754B2 JP6189754B2 (ja) | 2017-08-30 |
Family
ID=46798719
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556905A Expired - Fee Related JP6189754B2 (ja) | 2011-03-04 | 2012-03-02 | タンパク質を条件的に発現するベクター |
| JP2017044305A Withdrawn JP2017141245A (ja) | 2011-03-04 | 2017-03-08 | タンパク質を条件的に発現するベクター |
| JP2017125428A Withdrawn JP2017212995A (ja) | 2011-03-04 | 2017-06-27 | タンパク質を条件的に発現するベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044305A Withdrawn JP2017141245A (ja) | 2011-03-04 | 2017-03-08 | タンパク質を条件的に発現するベクター |
| JP2017125428A Withdrawn JP2017212995A (ja) | 2011-03-04 | 2017-06-27 | タンパク質を条件的に発現するベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9402919B2 (enExample) |
| EP (2) | EP2681327B1 (enExample) |
| JP (3) | JP6189754B2 (enExample) |
| CN (1) | CN103534355A (enExample) |
| AU (1) | AU2012225749B2 (enExample) |
| CA (1) | CA2828411A1 (enExample) |
| SG (2) | SG10201600912SA (enExample) |
| TW (1) | TWI582108B (enExample) |
| WO (1) | WO2012122025A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013158871A1 (en) * | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| EP3133923B1 (en) * | 2014-04-24 | 2020-06-03 | University of Florida Research Foundation, Inc. | Aav-based gene therapy for multiple sclerosis |
| WO2015164723A1 (en) * | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| CA2959104A1 (en) * | 2014-08-26 | 2016-03-03 | Hsf Pharmaceuticals | Novel immunization agents and methods of use |
| JP6383621B2 (ja) * | 2014-09-24 | 2018-08-29 | 太陽インキ製造株式会社 | 硬化性組成物、ドライフィルム、硬化物、プリント配線板およびプリント配線板の製造方法 |
| CN113999875A (zh) * | 2015-05-28 | 2022-02-01 | 康奈尔大学 | 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法 |
| US10214731B2 (en) | 2015-05-28 | 2019-02-26 | Cornell University | Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema |
| JP6907188B2 (ja) * | 2015-08-13 | 2021-07-21 | ダイアックス コーポレーション | 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 |
| WO2017062953A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| SG11201803934YA (en) | 2015-11-11 | 2018-06-28 | Intrexon Corp | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3235516B1 (en) * | 2016-04-22 | 2019-06-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | Regulatable adeno-associated virus (aav) vector |
| CA3025301A1 (en) * | 2016-05-25 | 2017-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Activity-dependent expression constructs and methods of using the same |
| CA3025667A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| WO2018089527A1 (en) * | 2016-11-09 | 2018-05-17 | Intrexon Corporation | Frataxin expression constructs |
| EP3568474A1 (en) | 2017-01-10 | 2019-11-20 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| CA3065930A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| US20190256867A1 (en) | 2018-02-01 | 2019-08-22 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
| KR20250136930A (ko) | 2018-03-06 | 2025-09-16 | 프레시전 인코포레이티드 | 사람 파필로마바이러스 백신 및 이의 용도 |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| EP3813854A4 (en) * | 2018-06-27 | 2022-06-08 | Precigen, Inc. | IN VIVO REGULATED POLYTHERAPY FOR THE TREATMENT OF CANCER |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| EP3921334A1 (en) | 2019-02-08 | 2021-12-15 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
| CN113454459A (zh) * | 2019-02-18 | 2021-09-28 | 利物浦大学 | 诊断方法 |
| US20220175781A1 (en) | 2019-03-08 | 2022-06-09 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| WO2021211640A1 (en) * | 2020-04-14 | 2021-10-21 | University Of Florida Research Foundation, Incorporated | Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis |
| WO2021211614A1 (en) | 2020-04-14 | 2021-10-21 | University Of Florida Research Foundation, Incorporated | Aav-based gene therapies for treatment of autoimmune diseases |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| CN112741895A (zh) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Epo类似物在制备治疗脓毒症药物中的应用 |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3360004A (en) | 1965-09-07 | 1967-12-26 | Bendix Corp | Pressure proportioning valve |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
| US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US20020107211A1 (en) * | 1995-06-07 | 2002-08-08 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5962311A (en) | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| ATE293699T1 (de) | 1995-03-03 | 2005-05-15 | Syngenta Participations Ag | Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand |
| PL323587A1 (en) | 1995-05-26 | 1998-04-14 | Zeneca Ltd | Gene changing-over system including edisone receptor |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| EP0874909A2 (en) * | 1996-08-23 | 1998-11-04 | Arch Development Corporation | Long-term expression of gene products by transforming muscle cells |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| EP0996735B1 (en) | 1997-06-09 | 2003-12-10 | Genvec, Inc. | Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus |
| US20100190692A1 (en) | 1997-07-04 | 2010-07-29 | Van Groeninghen Johannes C | Methods for reducing gnrh-positive tumor cell proliferation |
| WO1999002190A1 (en) * | 1997-07-11 | 1999-01-21 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| US20020048792A1 (en) | 1997-08-26 | 2002-04-25 | Ariad Gene Therapeutics, Inc. | Methods and materials for regulated production of proteins |
| US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
| JP2001517455A (ja) | 1997-09-23 | 2001-10-09 | ジェンベク、インコーポレイティッド | 真核生物ウイルスベクター構築用プラスミド |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| IL139040A0 (en) | 1998-04-22 | 2001-11-25 | Genvec Inc | Efficient purification of adenovirus |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| DE19831420A1 (de) * | 1998-07-14 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren |
| US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| US7030098B2 (en) | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| BR0010750A (pt) | 1999-05-17 | 2002-02-26 | Conjuchem Inc | Peptìdeos insulinotrópicos de longa duração |
| US6225895B1 (en) | 1999-05-26 | 2001-05-01 | Floyd E. Bigelow, Jr. | Towed vehicle monitor system |
| WO2001003722A1 (en) * | 1999-07-09 | 2001-01-18 | Mayo Foundation For Medical Education And Research | Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| AU2001249315A1 (en) | 2000-03-22 | 2001-10-03 | Rheogene, Inc. | Ecdysone receptor-based inducible gene expression system |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2002066614A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| EP1534738B1 (en) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| JP4955904B2 (ja) | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | 新規エクジソン受容体／無脊椎動物レチノイドｘ受容体−ベースの誘導性遺伝子発現システム |
| EP1372678A2 (en) * | 2001-03-09 | 2004-01-02 | Board of Regents, The University of Texas System | Vectors, compositions and methods for treating a vascular disorder |
| US20030091544A1 (en) * | 2001-03-13 | 2003-05-15 | Vical Incorporated | Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases |
| US7588758B2 (en) * | 2001-09-11 | 2009-09-15 | University Of Medicine And Dentistry Of New Jersey | COX-2 function and wound healing |
| US7919269B2 (en) | 2001-09-26 | 2011-04-05 | Intrexon Corporation | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| MXPA04002810A (es) | 2001-09-26 | 2005-06-06 | Rheogene Holdings Inc | Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos. |
| US20060052292A1 (en) | 2001-12-21 | 2006-03-09 | Maxygen Aps Maxygen Holdings, Ltd. | Adiponectin fragments and conjugates |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US20050228016A1 (en) | 2002-06-13 | 2005-10-13 | Enrique Michelotti | Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20040049437A1 (en) | 2002-09-11 | 2004-03-11 | Govone Solutions, Lp | Method, system and computer program product for automating transaction tax calculation |
| WO2004034971A2 (en) * | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20050089515A1 (en) | 2003-08-29 | 2005-04-28 | Dyax Corp. | Poly-pegylated protease inhibitors |
| WO2005026457A1 (en) | 2003-09-15 | 2005-03-24 | Jeong Ho Yang | Removable attachement-type shower unit |
| SG134333A1 (en) | 2003-11-12 | 2007-08-29 | Phenomix Corp | Heterocyclic boronic acid compounds |
| US20050145385A1 (en) | 2004-01-05 | 2005-07-07 | Nguyen Philip D. | Methods of well stimulation and completion |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| JP2007537755A (ja) | 2004-05-18 | 2007-12-27 | イントレクソン コーポレイション | Ｄｎａクローニングベクタープラスミドのダイナミックなベクター構築のための方法 |
| EP1778220A1 (en) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Constrained cyano compounds |
| US20060027071A1 (en) | 2004-08-06 | 2006-02-09 | Barnett Ronald J | Tensegrity musical structures |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| WO2006055973A2 (en) | 2004-11-22 | 2006-05-26 | University Of Utah Research Foundation | Erythropoietin for treatment of multi-organ failure |
| RU2007119585A (ru) | 2004-12-20 | 2009-01-27 | Вайет (Us) | Производные рапамицина и их применение при лечении неврологических заболеваний |
| NZ574663A (en) | 2004-12-20 | 2010-05-28 | Wyeth Corp | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| KR20080000665A (ko) | 2005-04-22 | 2008-01-02 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 디펩티딜 펩티다아제-ⅳ 억제제 |
| WO2006136450A2 (en) | 2005-06-23 | 2006-12-28 | Aplagen Gmbh | Supravalent compounds |
| JPWO2007074747A1 (ja) | 2005-12-26 | 2009-06-04 | 株式会社クラレ | 細胞培養用材料 |
| EP2001500A4 (en) | 2006-03-10 | 2010-07-28 | Dyax Corp | FORMULATIONS FOR ECALLANTIDE |
| US7851438B2 (en) * | 2006-05-19 | 2010-12-14 | GlycoFi, Incorporated | Erythropoietin compositions |
| PL2054074T3 (pl) * | 2006-08-04 | 2015-03-31 | Prolong Pharmaceuticals Llc | Zmodyfikowana erytropoetyna |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
| TWI407960B (zh) * | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| CA2689137C (en) | 2007-05-29 | 2017-05-02 | Intrexon Corporation | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| CA2698212A1 (en) | 2007-08-23 | 2009-02-26 | Intrexon Corporation | Methods and compositions for diagnosing disease |
| EP2205280B1 (en) | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
| MX2010003371A (es) | 2007-09-28 | 2010-05-05 | Intrexon Corp | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. |
| BRPI0818287A2 (pt) * | 2007-10-08 | 2015-11-03 | Intrexon Corp | células dendríticas manipuladas e usos para o tratamento do câncer. |
| US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| AU2009271129B2 (en) | 2008-07-14 | 2013-10-10 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| BR122012024318A2 (pt) | 2008-09-26 | 2019-07-30 | Ambrx, Inc. | Polipeptídeos modificados de eritropoetina animal e seus usos |
| RU2573912C2 (ru) * | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| JP6018753B2 (ja) | 2008-11-13 | 2016-11-02 | ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ | Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物 |
| ES2629630T3 (es) * | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
| US20100305002A1 (en) | 2009-04-27 | 2010-12-02 | Roswell Park Cancer Institute | Reagents and Methods for Producing Bioactive Secreted Peptides |
| KR20130010121A (ko) | 2010-03-23 | 2013-01-25 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| EP2808057B1 (en) | 2013-05-31 | 2016-02-03 | RaySearch Laboratories AB | Method and system for robust radiotherapy treatment planning |
-
2012
- 2012-03-02 JP JP2013556905A patent/JP6189754B2/ja not_active Expired - Fee Related
- 2012-03-02 EP EP12755403.8A patent/EP2681327B1/en not_active Not-in-force
- 2012-03-02 WO PCT/US2012/027515 patent/WO2012122025A2/en not_active Ceased
- 2012-03-02 US US14/001,943 patent/US9402919B2/en not_active Expired - Fee Related
- 2012-03-02 EP EP18188076.6A patent/EP3450568A3/en not_active Withdrawn
- 2012-03-02 AU AU2012225749A patent/AU2012225749B2/en not_active Ceased
- 2012-03-02 CN CN201280021577.XA patent/CN103534355A/zh active Pending
- 2012-03-02 CA CA2828411A patent/CA2828411A1/en not_active Abandoned
- 2012-03-02 SG SG10201600912SA patent/SG10201600912SA/en unknown
- 2012-03-02 SG SG2013063045A patent/SG192856A1/en unknown
- 2012-03-03 TW TW101107160A patent/TWI582108B/zh not_active IP Right Cessation
-
2016
- 2016-05-11 US US15/151,947 patent/US20160317678A1/en not_active Abandoned
-
2017
- 2017-03-08 JP JP2017044305A patent/JP2017141245A/ja not_active Withdrawn
- 2017-06-27 JP JP2017125428A patent/JP2017212995A/ja not_active Withdrawn
-
2018
- 2018-05-31 US US15/993,773 patent/US20180344876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512808A5 (enExample) | ||
| US12409236B2 (en) | Liver-specific nucleic acid regulatory elements and methods and use thereof | |
| JP2014526441A5 (enExample) | ||
| JP2017538395A (ja) | 代謝障害を処置するための組成物及びその使用方法 | |
| JP2010512795A5 (enExample) | ||
| JP2010202664A5 (enExample) | ||
| JP2015509504A5 (enExample) | ||
| Kappel et al. | Management of moyamoya disease: a review of current and future therapeutic strategies | |
| JP2016512205A5 (enExample) | ||
| WO2021016727A1 (zh) | 针对纤维化、炎症、和/或老化疾病的治疗药物 | |
| KR20180021736A (ko) | 세포의 항아폽토시스, 생존, 또는 증식을 유도하기 위한 조성물 및 방법 | |
| JP2014510730A5 (enExample) | ||
| Cheng et al. | New insights into circRNA and its mechanisms in angiogenesis regulation in ischemic stroke: a biomarker and therapeutic target | |
| Ding et al. | Genomic Editing of a Pathogenic Sequence Variant in ACTA2 Rescues Multisystemic Smooth Muscle Dysfunction Syndrome in Mice | |
| JP2015521611A5 (enExample) | ||
| JP2016508036A5 (enExample) | ||
| JP6532141B2 (ja) | 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物 | |
| JP2014512369A5 (enExample) | ||
| JP2016509018A5 (enExample) | ||
| Sharma et al. | The cellular stress response interactome and extracellular matrix cross-talk during fibrosis: a stressed extra-matrix affair | |
| during Fibrosis | The Cellular Stress Response | |
| WO2025137397A1 (en) | Lipid nanoparticles for inducing protein expression in the placenta | |
| HK40082999A (en) | Liver-specific nucleic acid regulatory elements and methods and use thereof | |
| US20180344804A1 (en) | Attenuation of intrapulmonary inflammation | |
| Butler-Browne | TI 4 Cell therapy and muscular dystrophy |